lymphocytes

[Lyell Immunopharma, Inc.] Lyell Immunopharma, Inc. announced that the US FDA has cleared an Investigational New Drug (IND) application to initiate a Phase I clinical trial for LYL132, an investigational T-cell receptor therapy for patients with solid tumors expressing New York esophageal squamous cell carcinoma 1 that the company is developing in collaboration with GSK.

[Cartesian Therapeutics] Cartesian Therapeutics announced that it has dosed the first patient in a Phase I/IIa multicenter clinical study evaluating Descartes-25, engineered to deliver a combination of synergistically active anti-myeloma therapies directly to tumor microenvironment, in patients with multiple myeloma.

[Marker Therapeutics, Inc.] Marker Therapeutics, Inc. announced that the US FDA Office of Orphan Products Development has granted Orphan Drug designation to MT-601, a multi-tumor-associated antigen-specific T cell product optimized for the treatment of patients with pancreatic cancer.

[Cell] Low serum magnesium levels were associated with more rapid disease progression and shorter overall survival in CAR T cell and immune checkpoint antibody-treated patients.

[Trends in Molecular Medicine] Natural killer (NK) cells lend themselves to off-the-shelf applications owing to their favorable safety profile and retained efficacy in an allogeneic setting.

[Molecular Therapy-Methods & Clinical Development] In a humanized mouse model under HIV-1 challenge, CXCR4-disrupted CD4+ T cells were enriched in the peripheral blood and spleen, indicating survival advantage due to resistance to viral infection.